Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 10/20 | 0.65 |
| ▸ | ADORA1 | P30542 | 9/20 | 0.65 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.60 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.60 |
| ▸ | MAPK8 | P45983 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | MAPK9 | P45984 | 4/20 | 0.44 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.44 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.44 |
| ▸ | RPS6KB2 | Q9UBS0 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.42 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5017620 | 0.91 | ADORA2A (0.68) | ADORA2AADORA1ADORA3ADORA2BMAPK8 | |
| SCHEMBL5022291 | 0.88 | ADORA2A (0.77) | ADORA2AADORA1ADORA3ADORA2BKDM4E | |
| SCHEMBL5016301 | 0.87 | ADORA2A (0.67) | ADORA2AADORA1ADORA3ADORA2BKDM4E | |
| SCHEMBL5016278 | 0.87 | ADORA2A (0.67) | ADORA2AADORA1ADORA3ADORA2BMAPK8 | |
| SCHEMBL5024936 | 0.86 | ADORA2A (0.69) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL5022206 | 0.85 | ADORA2A (0.67) | ADORA2AADORA1ADORA3ADORA2BKDM4E | |
| SCHEMBL6038222 | 0.82 | ADORA2A (0.66) | ADORA2AADORA1ADORA3ADORA2BKDM4E | |
| SCHEMBL5017747 | 0.82 | ADORA2A (0.65) | ADORA2AADORA1ADORA3ADORA2BKDM4E | |
| SCHEMBL5017779 | 0.82 | ADORA2A (0.60) | ADORA2AADORA1ADORA3ADORA2BPOLB | |
| SCHEMBL14264281 | 0.82 | ADORA2A (0.71) | ADORA2AADORA1ADORA3ADORA2BKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080058356-A1 | 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-03-06 | — | — | US | claimed |
| US-20080058356-A1 | 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-03-06 | — | — | US | disclosed |
| US-20080058356-A1 | 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-03-06 | — | — | US | disclosed |
| US-20080058356-A1 | 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-03-06 | — | — | US | disclosed |
| WO-2005058883-A1 | 2, 6 BISHETEROARYL-4-AMINOPYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS | ALMIRALL PRODESFARMA AG (CH) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058356-A1 | 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885ADORA1 3/4885ADORA3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.